New website provides overview and review of initiatives for access to medical products against Covid-19

Wemos has launched covid19response.org, a website that provides an up-to-date overview of international initiatives by public institutions to enhance access to medical products against Covid-19, such as vaccines, medicines and diagnostics. It presents their characteristics and reviews their potential to contribute to an equitable and effective response to the current and future pandemics, as well as the support they need to become successful. Among the assessed initiatives are COVAX, the TRIPS Waiver and the South African mRNA hub.

Equal access to Covid-19 innovations

To effectively combat the current and future pandemics, everyone in the world needs access to medical innovations. However, access is still highly unequal. High-income countries can vaccinate their population multiple times, while lower-income countries experience dire vaccine shortages. This disparity is unacceptable as it leads to avoidable deaths, hardship and economic damage. Wemos therefore advocates a system of medical innovation that primarily serves the global public interest instead of solely commercial or national interests.

Several public institutions, such as the World Health Organization, the World Bank and the European Commission, have started or proposed a wide variety of international initiatives to improve global access to key medical innovations. On covid19response.org, Wemos outlines these initiatives and assesses their potential to contribute to an equitable and effective Covid-19 response. These assessments are based on five main principles: 1) sufficiency, 2) urgency, 3) sustainability, 4) power balance, and 5) public first.

Increasing self-sufficiency

According to Wemos, achieving an equitable and effective Covid-19 response requires initiatives that increase the range of producers of Covid-19 innovations worldwide and contribute to self-sufficiency of low- and middle-income countries. This breaks dependencies on high-income countries and a few leading pharmaceutical companies, stimulates solutions for local context, and brings prices down. Investing in expanding local production capacity in low- and middle-income countries also improves resilience to future public health emergencies of local and international concern.

Wemos therefore calls upon policy makers around the world to support initiatives such as the Covid-19 Technology Access Pool (C-TAP) and Medicines Patent Pool (MPP) that facilitate the sharing of know-how and technology needed for production. Also the TRIPS Waiver proposal by India and South Africa requires full support, as it would allow qualified pharmaceutical companies other than the right holders to produce Covid-19 innovations. The South African mRNA hub is currently making great strides in developing its own mRNA vaccine. As it seeks to produce and distribute vaccines locally and provide capacity building in the region, the mRNA hub model presents a structural solution to current inequities in access with lasting effects beyond this pandemic.

Initiatives aiming to increase the funding for pandemic preparedness and response, including expansion of local manufacturing capacity, such as the G20’s Global Health Threats Fund and European Commission’s HERA, should champion democratic governance and attach conditions to their funding to ensure the sharing of know-how and technology needed for production and to foster fair pricing. Unfortunately, as the overview on covid19response.org shows, this is not yet a given.

For short-term relief, donating vaccines to low- and middle-income countries through COVAX should be intensified. Though, this cannot be considered a long-term solution as it perpetuates the dependence of low- and middle-income countries on high-income countries.

For the complete overview of initiatives and their reviews, please visit covid19response.org.

For more information about the context of the website and the methodology used for reviewing the initiatives, please visit covid19response.org/about.

The information on the website will be updated regularly, and more initiatives will be added in the (near) future.

Webinar

On Wednesday 2 March 2022 (3:00 – 4:30 PM (CET)), we will organise a webinar during which we will: 

  • explain the website and the principles we used to assess the initiatives, 
  • present the main conclusions and policy recommendations for an equitable and effective Covid-19 response, and 
  • aim to answer all your questions.

Please register via this link. See you there!


Leave a Reply

Your email address will not be published. Required fields are marked *

Recent News items

The Foreign Trade and Development Cooperation policy document does not sufficiently address access to healthcare for poorer people

14-07-2022

The new policy paper of Minister Schreinemacher of Foreign Trade and Development Cooperation, “Doen waar Nederland goed in is (“Doing what the Netherlands is good at”), is very much focused on Dutch business interests and seems to have insufficient attention for realising access to health care for poorer population groups. The Minister indicates that she wants to invest more in public-private collaborations in low- and middle-income countries, also in healthcare. As a result, there is a great risk that healthcare will become more commercial and therefore unaffordable for people with fewer financial resources. To provide good healthcare, the Minister should, instead, contribute to strengthening the capacity and financial resources in the public sector. 

Continue reading

What are best practices to address brain drain of health workers?

07-07-2022

What are best (regional) practices when it comes to addressing brain drain – i.e. the emigration of skilled workers, including health workers – and what action is needed on EU level? With this open consultation, the European Commission is interested in feedback on the scale and dynamics of brain drain, and in successful practices and regional strategies and policies to tackle the emigration of qualified workers. Wemos has provided input to the consultation. We recommend, for example, that EU Member States use existing instruments to implement policies and strategies based on evidence, to strengthen their health workforce.

Continue reading